hereditary cancer [1] . So far, only in a minority of cases different susceptibility genes (i.e., FOXE1, SRGAP1, SRRM2 and NKX2-1) or loci (i.e., 1q21, 2q21, 6q22, 8q24, 8p23.1-p22, 4q32, 14q32.13 and 19p13.2) have been identified in association with FNMTC etiology.
Introduction
Familial non-medullary thyroid carcinoma (FNMTC) is a rare thyroid disease [1] which occurs either as part of known hereditary syndromes or as non-syndromic isolated
Results
We investigated 63 patients belonging to 38 unrelated kindred showing the familial form of thyroid cancer (FTC). Nineteen out of 38 (50%) families had 2 affected members, 14/38 (36.8%) had 3 members with thyroid cancer and 5/38 (13.2%) had 4 or more affected members. All patients with FNMTC available for genetic analysis had the papillary histotype; 15 of them (23.8%) presented the follicular variant and 1 (1.6%) the Warthin-like variant. Of these patients, 40 (63.4%) had a parent-child relationship (22 kindred), 19 (30.2%) had a sibling relationship (13 kindred) and 4 (6.4%) had an uncle-niece relationship (3 kindred). Age at diagnosis of FNMTC group was 46 ± 15.5 years (range 15-78 years). Age at diagnosis of probands was 54.3 ± 9.3 (range 25-77 years), and that of affected familial members was 42.9 ± 15.7 (range 15-73 years). No thyroid cancer-associated syndrome was present clinically in our patients. Thyroid specimen of FNMTC patients was analyzed for classical point mutations and rearrangements [8] of thyroid cancer, and we found a 65% of BRAFV600E, 19% of RET/PTC and 16% of RAS point mutations. Clinical features of FNMTC patients are reported in Table 1 . In addition, we analyzed 41 unaffected family members of FNMTC patients (14 males and 27 females, mean age 44.4 ± 19 years, range 14-62 years) belonging to 25 kindred. Among FNMTC patients, 23 (36.5%) had a single nodule, whereas 40 (63.5%) patients had a history of multinodular goiter. At the time of the study, 57 (90.5%) were free of disease, 5 (7.9%) showed persistent disease and 1 (1.6%) was deceased for other causes. In the group of 41 unaffected family members, 33 (80.6%) patients had no evidence of thyroid nodule, 4 (9.7%) showed a multinodular goiter and 4 (9.7%) had a single nodule. In all cases, the FNAB indicated the presence of benign lesions. To identify whether the G534E variant (c. 1601 G>A) was involved with FNMTC development, genomic DNA belonging to FNMTC patients and unaffected siblings was amplified at 55 °C (35 cycles) with 1.5 mM MgCl 2 (PF: 5′-TGGTTCACGAGGATGAGCTT-3′; PR: 5′-TTGATG GTGGCTTTGATCCA-3′) and subsequently run with denaturing high-performance liquid chromatography (DHPLC) alone and mixed with an approximately equimolar volume of a WT sample to define the genotype of homoduplex samples and direct sequencing. Figure 1 shows a representative curve obtained with DHPLC (A) and the sequence of a familial patient (first generation) with a perfect wild-type profile (B). Similar curves and sequences were observed for all patients and unaffected family members, concluding for the absence of the G534E variant in our set of familial patients and relatives. The G534E was searched also at somatic level in 33 available cancer samples (33/63; 52.3%) and the corresponding normal counterparts. None of the tissue specimen displayed the variation.
In conclusions, in this study we analyzed 63 FNMTC patients for the presence of the G534E variant in HABP2 gene in order to correlate that variant with the predisposition to develop familial form of thyroid cancer demonstrated by clinical features of genetic anticipation, shorter telomere length and elevated genetic instability. All FNMTC patients displayed a genetic profile typical of homozygous wild type, demonstrating that the G534E variant is not necessarily associated with the development of familial form of thyroid cancer. In summary, the involvement of the G534E variant in FNMTC predisposition is still under debate. After the original work by Gara et al. [2] , only one study by Zhang et al. [2] manages to replicate the results in a subgroup of FNMTC. In this second work, none of the normal subjects from the analyzed kindred had the variant, whereas in other public databases its frequency has been reported from 2 to 4% in the general population and from 4 to 8% in sporadic thyroid cancer [2] . Since the data reported by Gara are convincing and corroborated by functional studies, we hypothesized that the discrepancy between our (and others) results and the data by Gara should be related to ethnic differences which seem to influence prevalence and importance of this variant. A large study with several kindred from different ethnicity is definitely needed.
Compliance with ethical standards
Conflict of interest The authors declare that they have no conflict of interest.
Ethical standards All procedures performed in this study were in accordance with the local ethical committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent Informed consent has been required and signed by each participant to the study. indicates the point of mutation G>A. As shown in the figure, the sequence is indicative of a wild-type subject
